Skip to content

Delcath Systems DCTH Current ratio

Current ratio at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
5.1×+0.2×
Boston Scientific logo
Boston ScientificBSX
1.9×+0.4×
Altimmune logo
AltimmuneALT
29.6×+13.7×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
2.6×+0.4×
Wave Life Sciences logo
Wave Life SciencesWVE
11.3×+8.3×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
2.1×-1.1×

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×

Where this comes from

Calculated from Delcath Systems’s reported figures.

Based on the most recent quarter.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's current ratio?
Delcath Systems (DCTH) reported current ratio of 11.2× in Q1 2026.
How has Delcath Systems's current ratio changed year-over-year?
Delcath Systems's current ratio decreased by 29.5% year-over-year, from 16× to 11.2×.
What is the long-term trend for Delcath Systems's current ratio?
Over 5 years (2020 to 2025), Delcath Systems's current ratio has grown at a 27.6% compound annual growth rate (CAGR), from 3.2× to 10.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.